Terrell v. Kiromic Biopharma, Inc.

Supreme Court of Delaware·Decided May 4, 2023·No. 299, 2022·Published

Opinion

IN THE SUPREME COURT OF THE STATE OF DELAWARE

JASON TERRELL, § § No. 299, 2022

Plaintiff Below, § Appellant, § Court Below: Court of Chancery § of the State of Delaware v. § § C.A. No. 2021-0248

KIROMIC BIOPHARMA, INC., § §

Defendant Below, § Appellee. §

Submitted: February 8, 2023 Decided: May 4, 2023

Before SEITZ, Chief Justice; VALIHURA and TRAYNOR, Justices. Upon appeal from the Court of Chancery. REVERSED AND REMANDED.

Scott James Leonhardt, Esquire, Jason A. Gibson, Esquire, THE ROSNER LAW GROUP LLC, Wilmington, Delaware; Alexander Klein, Esquire, (argued) BARKET EPSTEIN KEARON ALDEA & LOTURCO, LLP, Garden City, New York, for Appellant Jason Terrell.

Laurence V. Cronin, Esquire, Kelly A. Green, Esquire, SMITH, KATZENSTEIN & JENKINS, LLP, Wilmington, Delaware; Robert S. Friedman, Esquire, Joshua I. Schlenger, Esquire (argued), Katherine Anne Boy Skipsey, Esquire, SHEPPARD, MULLIN, RICHTER & HAMPTON, LLP, New York, New York, for Appellee Kiromic Biopharma, Inc.

TRAYNOR, Justice:

In an action seeking declaratory and injunctive relief, the Court of Chancery was asked to resolve a dispute between a company and one of its former directors over the meaning of a stock option agreement and option grant notice. Applying the plain text of the agreement, the Court of Chancery determined that the dispute was to be resolved in accordance with a board committee’s interpretation of the agreement and notice. After the board, acting through a committee, interpreted the agreement and notice in a manner favorable to the company, the Court of Chancery, without hearing further from the former director, promptly dismissed the former director’s complaint for lack of subject matter jurisdiction.

In this opinion, we hold that the Court of Chancery properly stayed the action to permit the board’s committee to interpret the agreement and notice in the first instance. We disagree, however, with the court’s decision to dismiss the former director’s complaint without any meaningful review of the committee’s interpretation. We therefore reverse the Court of Chancery’s order of dismissal and remand for a review of the committee’s conclusions consistent with the guidance provided in this opinion.

I

A

Dr. Jason Terrell is a former consultant to and director of Kiromic Biopharma, Inc., a Texas-based biopharmaceutical company incorporated in Delaware.1 He initially joined Kiromic as an outside consultant in 2014 before joining the company’s board in 2017. Terrell served on Kiromic’s board until irreconcilable differences caused him to resign his seat in 2019.

Terrell was compensated for his work at the company through three stock-

option grants, which, following Terrell’s and the Court of Chancery’s lead, we refer to as Agreements 1, 2, and 3. Agreement 1, which Kiromic and Terrell entered into on December 10, 2014, in exchange for his consulting services, granted Terrell options to purchase 500,000 shares of the company’s common stock at a strike price of $0.50 per share. The exercise term for these options was set to expire on December 10, 2024.

Agreement 2, entered into on January 23, 2017, to compensate Terrell for his appointment to the company’s board of directors, extended Terrell the right to purchase 500,004 shares of common stock at a strike price of $0.17 per share. The exercise term for this agreement was scheduled to expire on January 23, 2027.

1 We draw the relevant facts from Terrell’s March 22, 2021 Verified Complaint for Declaratory Judgment and Specific Performance and the documents attached to it as exhibits.

Terrell received his third, and final, grant of options on November 10, 2017, in exchange for his commitment to continue serving on the company’s board. Agreement 3 provided Terrell the option to purchase 500,004 shares of common stock at a strike price of $0.19 per share and, like the first two agreements, carried an exercise term of ten years.

Altogether these three stock-option agreements extended Terrell the right to purchase approximately 1.5 million shares of Kiromic common stock. This number comports with a 2015 email from Kiromic’s then-CEO to Terrell informing him: “you will receive in stock options your 500k shares for your consultant [sic] plus the 1 million shares for your position [o]n the board.”2 The dispute in this case arose out of the parties’ competing interpretations of Agreement 3. This agreement comprises three component parts: a Notice of Stock Option Grant (the “Grant Notice”), a Stock Option Agreement, and the 2017 Equity Incentive Plan. It also varies from the first two agreements in two critical respects. First, Agreement 3, unlike Agreements 1 and 2, contains a provision modifying its options in the event of a reverse stock split. Stock splits in 2019 and 2020 subsequently revised Terrell’s options under the third agreement to the right to purchase 14,285 shares of common stock at a strike price of approximately $6.65 per share.

2 App. to Opening Br. at A29.

This reduction in value to Agreement 3’s options magnified the agreement’s second critical difference from the earlier two: the existence of a provision in the Grant Notice that we will refer to as the “Release.” It is italicized and reads:

By signing this Grant Notice, you acknowledge and agree that other than the Shares [governed by the Grant Notice], you have no other rights to any other options, equity awards or other securities of the Company (except securities of the Company, if any, issued to you on or prior to the date hereof, if any), notwithstanding any commitment or communication regarding options, equity awards or other securities of the Company made prior to the date hereof, whether written or oral, including any reference to the contrary that may be set forth in your offer letter, consultant agreement or other documentation with the Company or any of its predecessors.3 Kiromic believes that this language extinguished Terrell’s right to the options

extended in Agreements 1 and 2, leaving Terrell with the right to purchase only 14,285 shares of the company’s common stock at a strike price of $6.65 per share. 4 Stated differently, it is Kiromic’s position that the option to purchase the 500,004 shares granted in Agreement 3 supplanted the options to purchase the one million shares granted in Agreements 1 and 2.

Terrell, on the other hand, contends that the parenthetical language, which excepts from the Release “securities of the Company, if any, issued to you on or prior to the date hereof, if any[,]” clearly preserves the options granted in Agreements 1 and 2.5 Terrell therefore maintains that he should have the right to

3 Id. at A35 (italics in original). 4 Id. at A112–13. 5 Id. at A130–31.

purchase 500,000 shares of Kiromic common stock at $0.50 per share; 500,004 shares at $0.17 per share; and 14,285 shares at $6.65 per share.

The parties’ divergent interpretations of Agreement 3 prompted Terrell to file a declaratory-judgment and specific-performance action in the Court of Chancery. Specifically, Terrell asked the court to declare that Agreements 1 and 2 remained valid and binding contracts and to compel Kiromic to reserve for the options provided in them. Kiromic responded by filing a motion to dismiss Terrell’s complaint for failing to state a claim upon which relief could be granted. The parties’ briefs on Kiromic’s motion addressed their competing interpretations of the Release.

While preparing for oral argument on the motion, the Court of Chancery discovered an alternative-dispute-resolution (“ADR”) provision in the parties’ Stock Option Agreement that appeared to govern its interpretation. The provision— Section 15.1—provides that:

Any dispute regarding the interpretation of this Agreement shall be submitted by Optionee or the Company to the Committee for review.

The resolution of such a dispute by the Committee shall be final and binding on the Company and Optionee.6

Free access — add to your briefcase to read the full text and ask questions with AI

Terrell v. Kiromic Biopharma, Inc., (Del. 2023).

Terrell v. Kiromic Biopharma, Inc. (Terrell v. Kiromic Biopharma, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Airborne Health, Inc. v. Squid Soap, LP
984 A.2d 126 (Court of Chancery of Delaware, 2009)
Dunlap v. State Farm Fire & Casualty Co.
878 A.2d 434 (Supreme Court of Delaware, 2005)
Graham v. State Farm Mutual Automobile Insurance
565 A.2d 908 (Supreme Court of Delaware, 1989)
Public Water Supply Co. v. DiPasquale
735 A.2d 378 (Supreme Court of Delaware, 1999)
Ryan v. Weiner
610 A.2d 1377 (Court of Chancery of Delaware, 1992)
Munyan v. Daimler Chrysler Corp.
909 A.2d 133 (Supreme Court of Delaware, 2006)
Precision Air, Inc. v. Standard Chlorine of Delaware, Inc.
654 A.2d 403 (Supreme Court of Delaware, 1995)
Levinson v. Delaware Compensation Rating Bureau, Inc.
616 A.2d 1182 (Supreme Court of Delaware, 1992)
Gilbert v. El Paso Co.
490 A.2d 1050 (Court of Chancery of Delaware, 1984)
James & Jackson, LLC. v. Willie Gary, LLC.
906 A.2d 76 (Supreme Court of Delaware, 2006)
CIGNA Ins. Co. v. Didimoi Prop. Holdings, NV
110 F. Supp. 2d 259 (D. Delaware, 2000)
Matter of Delmar Box Co.(ætna Ins. Co.)
127 N.E.2d 808 (New York Court of Appeals, 1955)
Ketler v. PFPA, LLC
132 A.3d 746 (Supreme Court of Delaware, 2016)
Gilbert v. El Paso Co.
575 A.2d 1131 (Supreme Court of Delaware, 1990)
Aiu Insurance Company v. Lexes
815 A.2d 312 (Supreme Court of Delaware, 2003)
Martin Marietta Materials, Inc. v. Vulcan Materials Co.
56 A.3d 1072 (Court of Chancery of Delaware, 2012)
Adkins Ltd. Partnership v. O Street Management, LLC
56 A.3d 1159 (District of Columbia Court of Appeals, 2012)
Cambridge Street Metal Co. v. Corrao
566 N.E.2d 1145 (Massachusetts Appeals Court, 1991)